- Home
- IFRX vs NKLA Comparison
IFRX vs NKLA Comparison
Compare IFRX & NKLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- NKLA
- Stock Information
- Founded
- IFRX 2007
- NKLA 2015
- Country
- IFRX Germany
- NKLA United States
- Employees
- IFRX N/A
- NKLA N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- NKLA Auto Manufacturing
- Sector
- IFRX Health Care
- NKLA Consumer Discretionary
- Exchange
- IFRX Nasdaq
- NKLA Nasdaq
- Market Cap
- IFRX 117.8M
- NKLA 98.8M
- IPO Year
- IFRX 2017
- NKLA N/A
- Fundamental
- Price
- IFRX $1.83
- NKLA $0.38
- Analyst Decision
- IFRX Strong Buy
- NKLA Hold
- Analyst Count
- IFRX 1
- NKLA 4
- Target Price
- IFRX $8.00
- NKLA $6.00
- AVG Volume (30 Days)
- IFRX 498.3K
- NKLA 30.7M
- Earning Date
- IFRX 03-20-2025
- NKLA 03-04-2025
- Dividend Yield
- IFRX N/A
- NKLA N/A
- EPS Growth
- IFRX N/A
- NKLA N/A
- EPS
- IFRX N/A
- NKLA N/A
- Revenue
- IFRX $187,930.00
- NKLA $75,529,000.00
- Revenue This Year
- IFRX $396.02
- NKLA $215.41
- Revenue Next Year
- IFRX $155.22
- NKLA $167.59
- P/E Ratio
- IFRX N/A
- NKLA N/A
- Revenue Growth
- IFRX 177.12
- NKLA 153.71
- 52 Week Low
- IFRX $1.17
- NKLA $0.35
- 52 Week High
- IFRX $2.82
- NKLA $34.50
- Technical
- Relative Strength Index (RSI)
- IFRX 32.97
- NKLA 34.43
- Support Level
- IFRX $1.76
- NKLA $0.35
- Resistance Level
- IFRX $1.98
- NKLA $0.53
- Average True Range (ATR)
- IFRX 0.19
- NKLA 0.12
- MACD
- IFRX -0.08
- NKLA -0.00
- Stochastic Oscillator
- IFRX 6.65
- NKLA 5.73
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About NKLA Nikola Corporation
Nikola Corp is a technology innovator and integrator, working to develop inventive energy and transportation solutions. It works on a business model that enables customers and fleets to integrate next-generation truck technology, hydrogen fueling and charging infrastructure, and related maintenance. It operates in two business units: Truck and Energy. The Truck business unit and Energy business unit. The Truck business unit is engaged manufacturing and selling FCEV and BEV trucks that provide, environmentally friendly, cost effective solutions to the trucking sector. The Energy business unit is engaged in developing and constructing a network of hydrogen fueling stations to meet hydrogen fuel demand for the Company's customers.